FEATURED ARTICLES
-
A Site Bio-Decontamination Strategy: From Equipment Qualification To Process Ownership
Pharmaceutical manufacturers can evolve beyond an OEM-developed or qualified cycle to a proactive, well-defined and controlled bio-decontamination strategy that supports a defensible validation package.
WHITE PAPERS & CASE STUDIES
-
Why Smarter Handling Can Save Your Production Line From Inefficiencies
Line performance in packaging is often decided between machines, not within them. Treating handling as a discipline rather than an afterthought changes how flow, protection, and growth are planned.
-
Managing Risks With Potent Pharmaceutical Products
Manufacturing potent medications safely requires specialized containment, toxicology expertise, and strict contamination controls to ensure compliance, product quality, and worker safety.
-
Transforming QC Lab Scheduling In Pharmaceutical Manufacturing
QC lab scheduling in GMP facilities often runs on static tools disconnected from production. Synchronizing the two in real time changes how batch release, deviations, and capacity are managed.
-
Your Quality Team Is Already Using AI To Draft Compliance Documents
Quality teams already use general-purpose AI for deviations and submission drafts without validation. Regulators expect governance, and the gap is an undocumented process step, not unreliable output.
-
Why Passing Audits No Longer Predicts Scale
Clean audit results confirm past compliance but say little about future performance. As products, markets, and regulations multiply, readiness depends on whether evidence stays connected.
-
Why Audit Success No Longer Predicts Clinical-Stage Performance
Passing inspections no longer signals that a growth-stage biotech can sustain clinical-stage complexity. The gap between audit readiness and operational readiness opens quietly.